Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 1
2017 1
2018 3
2019 5
2020 5
2021 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Results by year

Filters applied: . Clear all
Page 1
Targeting the Interplay between Epithelial-to-Mesenchymal-Transition and the Immune System for Effective Immunotherapy.
Soundararajan R, Fradette JJ, Konen JM, Moulder S, Zhang X, Gibbons DL, Varadarajan N, Wistuba II, Tripathy D, Bernatchez C, Byers LA, Chang JT, Contreras A, Lim B, Parra ER, Roarty EB, Wang J, Yang F, Barton M, Rosen JM, Mani SA. Soundararajan R, et al. Among authors: roarty eb. Cancers (Basel). 2019 May 24;11(5):714. doi: 10.3390/cancers11050714. Cancers (Basel). 2019. PMID: 31137625 Free PMC article. Review.
Genotype-Specific Differences in Circulating Tumor DNA Levels in Advanced NSCLC.
Lam VK, Zhang J, Wu CC, Tran HT, Li L, Diao L, Wang J, Rinsurongkawong W, Raymond VM, Lanman RB, Lewis J, Roarty EB, Roth J, Swisher S, Lee JJ, Gibbons DL, Papadimitrakopoulou VA, Heymach JV. Lam VK, et al. Among authors: roarty eb. J Thorac Oncol. 2021 Apr;16(4):601-609. doi: 10.1016/j.jtho.2020.12.011. Epub 2020 Dec 31. J Thorac Oncol. 2021. PMID: 33388476 Free PMC article.
Programmed Death-Ligand 1 Heterogeneity and Its Impact on Benefit From Immune Checkpoint Inhibitors in NSCLC.
Hong L, Negrao MV, Dibaj SS, Chen R, Reuben A, Bohac JM, Liu X, Skoulidis F, Gay CM, Cascone T, Mitchell KG, Tran HT, Le X, Byers LA, Sepesi B, Altan M, Elamin YY, Fossella FV, Kurie JM, Lu C, Mott FE, Tsao AS, Rinsurongkawong W, Lewis J, Gibbons DL, Glisson BS, Blumenschein GR Jr, Roarty EB, Futreal PA, Wistuba II, Roth JA, Swisher SG, Papadimitrakopoulou VA, Heymach JV, Lee JJ, Simon GR, Zhang J. Hong L, et al. Among authors: roarty eb. J Thorac Oncol. 2020 Sep;15(9):1449-1459. doi: 10.1016/j.jtho.2020.04.026. Epub 2020 May 8. J Thorac Oncol. 2020. PMID: 32389639 Free article.
Simplified molecular classification of lung adenocarcinomas based on EGFR, KRAS, and TP53 mutations.
Ruiz-Cordero R, Ma J, Khanna A, Lyons G, Rinsurongkawong W, Bassett R, Guo M, Routbort MJ, Zhang J, Skoulidis F, Heymach J, Roarty EB, Tang Z, Medeiros LJ, Patel KP, Luthra R, Roy-Chowdhuri S. Ruiz-Cordero R, et al. Among authors: roarty eb. BMC Cancer. 2020 Jan 31;20(1):83. doi: 10.1186/s12885-020-6579-z. BMC Cancer. 2020. PMID: 32005111 Free PMC article.
Multiregion gene expression profiling reveals heterogeneity in molecular subtypes and immunotherapy response signatures in lung cancer.
Lee WC, Diao L, Wang J, Zhang J, Roarty EB, Varghese S, Chow CW, Fujimoto J, Behrens C, Cascone T, Peng W, Kalhor N, Moran CA, Weissferdt A, Johnson FM, William WN Jr, Swisher SG, Lee JJ, Hong WK, Heymach JV, Wistuba II, Futreal PA, Zhang J. Lee WC, et al. Among authors: roarty eb. Mod Pathol. 2018 Jun;31(6):947-955. doi: 10.1038/s41379-018-0029-3. Epub 2018 Feb 6. Mod Pathol. 2018. PMID: 29410488 Free article.
The Prognostic and Therapeutic Role of Genomic Subtyping by Sequencing Tumor or Cell-Free DNA in Pulmonary Large-Cell Neuroendocrine Carcinoma.
Zhuo M, Guan Y, Yang X, Hong L, Wang Y, Li Z, Chen R, Abbas HA, Chang L, Gong Y, Wu N, Zhong J, Chen W, Chen H, Dong Z, Zhu X, Li J, Wang Y, An T, Wu M, Wang Z, Wang J, Roarty EB, Rinsurongkawong W, Lewis J, Roth JA, Swisher SG, Lee JJ, Heymach JV, Wistuba II, Kalhor N, Yang L, Yi X, Futreal PA, Glisson BS, Xia X, Zhang J, Zhao J. Zhuo M, et al. Among authors: roarty eb. Clin Cancer Res. 2020 Feb 15;26(4):892-901. doi: 10.1158/1078-0432.CCR-19-0556. Epub 2019 Nov 6. Clin Cancer Res. 2020. PMID: 31694833 Free PMC article.
Molecular Landscape of BRAF-Mutant NSCLC Reveals an Association Between Clonality and Driver Mutations and Identifies Targetable Non-V600 Driver Mutations.
Negrao MV, Raymond VM, Lanman RB, Robichaux JP, He J, Nilsson MB, Ng PKS, Amador BE, Roarty EB, Nagy RJ, Banks KC, Zhu VW, Ng C, Chae YK, Clarke JM, Crawford JA, Meric-Bernstam F, Ignatius Ou SH, Gandara DR, Heymach JV, Bivona TG, McCoach CE. Negrao MV, et al. Among authors: roarty eb. J Thorac Oncol. 2020 Oct;15(10):1611-1623. doi: 10.1016/j.jtho.2020.05.021. Epub 2020 Jun 13. J Thorac Oncol. 2020. PMID: 32540409 Free PMC article.
Targeted Tissue and Cell-Free Tumor DNA Sequencing of Advanced Lung Squamous-Cell Carcinoma Reveals Clinically Significant Prevalence of Actionable Alterations.
Lam VK, Tran HT, Banks KC, Lanman RB, Rinsurongkawong W, Peled N, Lewis J, Lee JJ, Roth J, Roarty EB, Swisher S, Talasaz A, Futreal PA, Papadimitrakopoulou V, Heymach JV, Zhang J. Lam VK, et al. Among authors: roarty eb. Clin Lung Cancer. 2019 Jan;20(1):30-36.e3. doi: 10.1016/j.cllc.2018.08.020. Epub 2018 Sep 5. Clin Lung Cancer. 2019. PMID: 30279110 Free article.
PD-L1 Expression, Tumor Mutational Burden, and Cancer Gene Mutations Are Stronger Predictors of Benefit from Immune Checkpoint Blockade than HLA Class I Genotype in Non-Small Cell Lung Cancer.
Negrao MV, Lam VK, Reuben A, Rubin ML, Landry LL, Roarty EB, Rinsurongkawong W, Lewis J, Roth JA, Swisher SG, Gibbons DL, Wistuba II, Papadimitrakopoulou V, Glisson BS, Blumenschein GR Jr, Lee JJ, Heymach JV, Zhang J. Negrao MV, et al. Among authors: roarty eb. J Thorac Oncol. 2019 Jun;14(6):1021-1031. doi: 10.1016/j.jtho.2019.02.008. Epub 2019 Feb 16. J Thorac Oncol. 2019. PMID: 30780001 Free article.
12 results